Ferring Pharma acquires Rebiotix and its microbiome therapy platform

Ferring Pharmaceuticals inked a deal to acquire Rebiotix and its platform of living drugs for an undisclosed amount, the companies announced today.

The Roseville, Minn.-based company is developing a microbiome-based therapy to prevent recurrent Clostridium difficile infection. Its Microbiota Restoration Therapy, which is delivered via enema or a lyophilized, non-frozen oral capsule, is designed to supply a patient’s intestinal tract with an array of healthy, human-derived microbes.

Get the full story at our sister site, Drug Delivery Business News.

The post Ferring Pharma acquires Rebiotix and its microbiome therapy platform appeared first on MassDevice.

from MassDevice https://ift.tt/2GRFiQz